샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792864

세계의 테라노스틱스 시장

Theranostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 472 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

테라노스틱스 세계 시장은 2030년까지 46억 달러에 달할 전망

2024년에 20억 달러로 추정되는 테라노스틱스 세계 시장은 2030년에는 46억 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 15.2%로 성장할 것으로 예측됩니다. 테라노스틱스 기계는 이 보고서에서 분석한 부문 중 하나로 CAGR은 14.8%를 기록하며 분석 기간 종료시에는 27억 달러에 달할 것으로 예측됩니다. 테라노스틱스 시약 부문의 성장률은 분석 기간 동안 CAGR 16.3%로 추정됩니다.

미국 시장은 5억 4,060만 달러로 추정, 중국은 CAGR 20.1%로 성장 예측

미국의 테라노스틱스 시장은 2024년에 5억 4,060만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 20.1%로 2030년까지 예측 시장 규모 9억 9,790만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 11.2%와 13.6%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.1%로 성장할 것으로 예측됩니다.

세계의 테라노스틱스 시장 - 주요 동향과 촉진요인 정리

테라노스틱스는 정밀의료의 미래인가, 아니면 시작에 불과한가?

영상 진단과 표적치료의 융합인 테라노스틱스는 현대 헬스케어의 가장 혁신적인 트렌드 중 하나입니다. 이 접근법은 임상의가 단일 분자 플랫폼을 사용하여 질병을 감지, 모니터링 및 치료할 수 있게 해주며, 종종 방사성 표지 약물이나 동반진단 약물을 사용하여 개별화된 치료 전략을 유도합니다. 초기에는 종양학, 특히 전립선, 갑상선, 신경내분비종양에 중점을 두었지만, 테라노스틱스는 심장병학, 신경학, 염증성 질환 등 다른 분야로 빠르게 확장하고 있습니다. 분자진단과 표적 치료 전달을 결합함으로써, 이 이중 기능적 양태는 만성질환과 생명을 위협하는 질병을 식별하고 치료하는 방법을 재정의하고 있습니다.

테라노스틱스의 특징은 환자 맞춤형 치료가 가능하다는 점입니다. 테라노스틱스는 치료 효과에 대한 실시간 피드백, 질병 진행의 조기 발견, 치료 요법의 신속한 조정을 가능하게 합니다. 이를 통해 비효율적인 치료에 대한 노출을 줄이고 부작용을 최소화할 수 있습니다. 헬스케어가 개인화된 치료 모델로 전환하는 가운데, 테라노스틱스는 획일적인 프로토콜에 대한 설득력 있는 대안을 제시합니다. 핵의학에서 루테튬-177이나 갈륨-68과 같은 방사선 장애 치료제의 채택은 생존율과 삶의 질 향상에 있어 유망한 결과를 보여주고 있습니다. 이러한 발전은 규제 당국의 승인, 방사성의약품 제조에 대한 투자, 종양학자, 방사선과 의사, 분자생물학자 간의 다학제적 협력도 가속화하고 있습니다.

영상기술과 방사성의약품은 어떻게 치료 효과를 향상시키고 있는가?

테라노스틱스의 진화는 핵 이미징 기술의 발전과 새로운 방사성의약품의 개발과 밀접한 관련이 있습니다. PET(양전자방사선단층촬영) 및 SPECT(단광자방사선단층촬영) 이미지는 분자 수준에서 질병 바이오마커를 식별하기 위한 초석이 되고 있습니다. 악성 세포에 세포 독성 효과를 주는 표적 동위원소와 결합하면 이러한 진단 도구는 치료 벡터가 될 수 있습니다. 악티늄225나 루테튬177과 같은 알파선이나 베타선을 방출하는 동위원소를 사용할 수 있게 되면서 전신 독성을 최소화하면서 내성 암을 치료할 수 있는 새로운 길이 열렸습니다.

또한, 표적 치료제와 병행하여 동반진단약이 개발되어 보다 정확한 임상적 판단의 지침이 되고 있습니다. PSMA(전립선 특이적 막 항원)와 소마토스타틴 수용체 등의 분자 마커는 현재 환자 계층화, 치료 적격성 판단, 치료 반응 모니터링에 사용되고 있습니다. 사이클로트론과 발전기를 이용한 방사성동위원소 생산의 증가는 특히 지역 및 민간 의료 환경에서 이러한 약품에 대한 접근성을 향상시키고 있습니다. 또한, 나노기술은 종양 표적화 강화, 신독성 감소, 순환 시간 연장을 제공하는 세라노시스 약물을 캡슐화하여 전달하기 위해 연구되고 있습니다. 이러한 혁신은 환자의 예후를 개선할 뿐만 아니라 테라노스틱스를 표준화하여 보다 광범위한 임상 적용을 가능하게 합니다.

테라노스틱스는 암 치료의 경제성과 치료 성적을 재구축할 수 있을까?

테라노스틱스는 장기적인 치료 비용을 줄이면서 임상 결과를 개선할 수 있는 강력한 도구로 부상하고 있습니다. 반응자를 조기에 식별하고 높은 정확도로 치료함으로써, 세라노스틱 요법은 치료 주기가 짧고 부작용이 적은 경우가 많으며, 그 결과 입원 기간을 단축하고 자원 배분을 개선할 수 있습니다. 정밀의학이 전 세계적으로 확산됨에 따라, 테라노스틱스는 암 치료 알고리즘과 임상 경로에 통합되고 있습니다. 의료기술평가(HTA) 기관과 의료비 지불기관은 특히 전이성 암과 말기 암에서 기존 치료의 효과가 적은 전이성 암과 말기 암에 대한 경제적 가치를 점차 인정하고 있습니다.

인프라 투자도 이러한 추세를 따르고 있습니다. 병원과 연구기관은 방사성의약품 생산능력, 사이클로트론 설치, 전문 영상 진단 연구실 구축을 통해 세라노시스 치료에 대한 수요 증가에 대응하고 있습니다. 핵의학 전문가, 의학물리학자, 방사성 종양 전문의 양성 프로그램은 특히 유럽, 북미, 아시아태평양에서 확대되고 있습니다. 동시에 생명공학 기업, 방사성의약품 기업, 학술센터 간의 협력으로 임상시험과 규제 당국에의 신청이 가속화되고 있습니다. 이러한 통합된 생태계는 테라노스틱스가 최후의 보루 같은 치료나 틈새 연구가 아닌 암 치료의 표준이 될 수 있는 토대를 마련하고 있습니다.

테라노스틱스 시장의 급성장 원동력은?

테라노스틱스 시장의 성장은 임상적, 기술적, 경제적 동향에 기반한 몇 가지 상호 연관된 요인에 의해 주도되고 있습니다. 첫째, 암과 신경 퇴행성 질환의 발병률이 증가함에 따라 의료 시스템은 보다 정밀하고 효율적이며 개인화된 치료법을 도입해야 합니다. 둘째, 방사성의약품과 동반진단약물의 급속한 발전으로 오프타겟 효과를 줄인 이중기능을 제공하는 질환 특이적 치료제의 개발이 가능해졌습니다.

셋째, PET/SPECT 스캐너와 디지털 영상 진단 플랫폼의 보급을 포함한 핵의학 영상 진단 인프라의 개선으로 선진국 시장에서도 신흥국 시장에서도 진단유도치료가 더욱 친숙해지고 있습니다. 넷째, 제약기업과 정부기관의 정밀의료 연구에 대한 투자가 확대되면서 파이프라인의 혁신과 임상시험의 빠른 진행을 촉진하고 있습니다. 다섯째, 특히 암 영역에서 특정 치료제에 유리한 약사 규제나 패스트트랙 지정이 이루어짐에 따라 시장 출시까지의 시간이 단축되어 상업적 도입이 촉진되고 있습니다. 마지막으로, 영상 해석과 치료 계획에서 AI와 머신러닝의 통합으로 진단 정확도가 향상되고 치료가 최적화되고 있습니다. 이러한 요소들이 복합적으로 작용하여 테라노스틱스는 환자 중심의 차세대 헬스케어에서 매우 중요한 역할을 하고 있습니다.

부문

제품(테라노스틱스 기기, 테라노스틱스 시약, 테라노스틱스 소프트웨어), 기술(유전체 기술, 단백질체학 기술, 대사체학 기술, 바이오마커 기술), 용도(종양학 용도, 신경학 용도, 순환기학 용도, 감염증 용도), 최종 용도(병원, 진단 실험실, 연구기관)

조사 대상 기업 사례

  • Abbott Laboratories
  • Agilent Technologies
  • Alpha9 Theranostics
  • Bayer AG
  • Beckman Coulter(Danaher)
  • Cardinal Health
  • Curium Pharma
  • GE HealthCare
  • Illumina Inc.
  • Lantheus Holdings
  • Molecular Theranostics LLC
  • Myriad Genetics
  • Novartis AG
  • Pfizer Inc.
  • Philips HealthCare
  • Qiagen N.V.
  • Radiopharm Theranostics(RAD)
  • RaySearch Laboratories
  • Siemens Healthineers
  • Telix Pharmaceuticals

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.27

Global Theranostics Market to Reach US$4.6 Billion by 2030

The global market for Theranostics estimated at US$2.0 Billion in the year 2024, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Theranostics Instruments, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Theranostics Reagents segment is estimated at 16.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$540.6 Million While China is Forecast to Grow at 20.1% CAGR

The Theranostics market in the U.S. is estimated at US$540.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$997.9 Million by the year 2030 trailing a CAGR of 20.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.2% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Theranostics Market - Key Trends & Drivers Summarized

Is Theranostics the Future of Precision Medicine, or Just the Start?

Theranostics, the fusion of diagnostic imaging and targeted therapy, represents one of the most transformative trends in modern healthcare. This approach enables clinicians to detect, monitor, and treat diseases using a single molecular platform, often with radiolabeled agents or companion diagnostics that guide personalized treatment strategies. While initially focused on oncology-particularly for prostate, thyroid, and neuroendocrine tumors-theranostics is rapidly expanding into other areas such as cardiology, neurology, and inflammatory diseases. By linking molecular diagnostics to targeted therapeutic delivery, this dual-function modality is redefining how chronic and life-threatening diseases are identified and treated.

What sets theranostics apart is its capacity for patient-specific treatment. It allows for real-time feedback on therapeutic efficacy, early detection of disease progression, and rapid adjustment of therapeutic regimens. This reduces exposure to ineffective therapies and minimizes side effects. As healthcare moves toward individualized treatment models, theranostics offers a compelling alternative to one-size-fits-all protocols. The adoption of radiotheranostic agents like Lutetium-177 and Gallium-68 in nuclear medicine has shown promising results in improving survival rates and quality of life. These developments are also accelerating regulatory recognition, investment in radiopharmaceutical production, and cross-disciplinary collaboration between oncologists, radiologists, and molecular biologists.

How Are Imaging Technologies and Radiopharmaceuticals Advancing Theranostic Efficacy?

The evolution of theranostics is closely linked to advances in nuclear imaging technologies and the development of novel radiopharmaceutical agents. PET (positron emission tomography) and SPECT (single-photon emission computed tomography) imaging have become cornerstones in identifying disease biomarkers at the molecular level. When paired with targeted isotopes that deliver cytotoxic effects to malignant cells, these diagnostic tools become therapeutic vectors. The increasing availability of alpha and beta-emitting isotopes-such as Actinium-225 and Lutetium-177-has opened new avenues for treating resistant cancers while minimizing systemic toxicity.

In addition, companion diagnostics are being developed alongside targeted therapies to guide clinical decisions with higher precision. Molecular markers such as PSMA (Prostate-Specific Membrane Antigen) and somatostatin receptors are now being used to stratify patients, determine eligibility for therapy, and monitor treatment response. The rise of cyclotron and generator-based radioisotope production is improving access to these agents, particularly in regional and private healthcare settings. Moreover, nanotechnology is being explored to encapsulate and deliver theranostic agents, offering enhanced tumor targeting, reduced renal toxicity, and prolonged circulation times. These breakthroughs are not only improving patient outcomes but also standardizing theranostics for broader clinical application.

Can Theranostics Reshape the Economics and Outcomes of Cancer Care?

Theranostics is emerging as a powerful tool for improving clinical outcomes while reducing long-term treatment costs-an increasingly important consideration in value-based healthcare systems. By identifying responders early and delivering therapy with high precision, theranostic regimens often require fewer treatment cycles and generate fewer side effects, resulting in shorter hospital stays and better resource allocation. As precision medicine initiatives gain traction globally, theranostics is being integrated into oncology treatment algorithms and clinical pathways. Health technology assessment (HTA) bodies and payers are gradually acknowledging its economic value, particularly in metastatic and late-stage cancers where traditional treatments offer diminishing returns.

Infrastructure investments are also following this trend. Hospitals and research institutions are building out radiopharmaceutical manufacturing capabilities, cyclotron installations, and specialized imaging labs to accommodate the rising demand for theranostic services. Training programs for nuclear medicine professionals, medical physicists, and theranostic oncologists are expanding, especially in Europe, North America, and Asia-Pacific. At the same time, collaborations between biotech firms, radiopharmaceutical companies, and academic centers are accelerating clinical trials and regulatory submissions. This integrated ecosystem is laying the groundwork for theranostics to become a standard component of cancer care rather than a last-resort treatment or research niche.

What’s Fueling the Rapid Expansion of the Theranostics Market?

The growth in the theranostics market is driven by several interconnected factors grounded in clinical, technological, and economic trends. First, the increased incidence of cancer and neurodegenerative diseases is prompting healthcare systems to adopt more precise, efficient, and personalized treatment modalities. Second, rapid advancements in radiopharmaceuticals and companion diagnostics are enabling the development of disease-specific theranostic agents that offer dual functionality with reduced off-target effects.

Third, improvements in nuclear imaging infrastructure-including broader deployment of PET/SPECT scanners and digital imaging platforms-are making diagnostic-guided therapy more accessible across both developed and emerging markets. Fourth, growing investments from pharmaceutical companies and government bodies in precision medicine research are fueling pipeline innovation and fast-tracking clinical trials. Fifth, favorable regulatory pathways and fast-track designations for certain theranostic drugs-especially in oncology-are reducing time-to-market and encouraging commercial uptake. Lastly, the integration of AI and machine learning in image interpretation and treatment planning is improving diagnostic accuracy and optimizing therapy delivery. Collectively, these drivers are positioning theranostics as a pivotal force in next-generation, patient-centered healthcare.

SCOPE OF STUDY:

The report analyzes the Theranostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Theranostics Instruments, Theranostics Reagents, Theranostics Software); Technology (Genomics Technology, Proteomics Technology, Metabolomics Technology, Biomarkers Technology); Application (Oncology Application, Neurology Application, Cardiology Application, Infectious Diseases Application); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Agilent Technologies
  • Alpha9 Theranostics
  • Bayer AG
  • Beckman Coulter (Danaher)
  • Cardinal Health
  • Curium Pharma
  • GE HealthCare
  • Illumina Inc.
  • Lantheus Holdings
  • Molecular Theranostics LLC
  • Myriad Genetics
  • Novartis AG
  • Pfizer Inc.
  • Philips HealthCare
  • Qiagen N.V.
  • Radiopharm Theranostics (RAD)
  • RaySearch Laboratories
  • Siemens Healthineers
  • Telix Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Theranostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Adoption of Personalized Medicine Drives Growth in Theranostic Platforms
    • Expansion of Companion Diagnostics in Oncology Enhances Targeted Drug Efficacy
    • Increased Use of Theranostics in Nuclear Medicine Supports Precision Imaging and Therapy
    • Integration of Diagnostic Imaging With Targeted Radiotherapy Boosts Clinical Workflow Efficiency
    • Growth in Radioisotope Development Enhances Dual-Function Diagnostic-Therapeutic Agents
    • Demand for Early Detection and Monitoring of Tumor Response Strengthens Theranostic Relevance
    • Increased Funding for Radiotheranostic Trials Expands Clinical Validation Across Cancer Types
    • Availability of PET/CT and SPECT Technologies Supports Platform Compatibility
    • Advancements in Molecular Imaging Tracers Improve Disease-Specific Targeting
    • Regulatory Fast-Tracking for Breakthrough Theranostic Drugs Encourages Market Entry
    • Adoption in Multi-Modal Oncology Clinics Supports Real-Time Treatment Optimization
    • Expansion of Biomarker-Guided Therapy in Autoimmune and Neurological Disorders Extends Market Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Theranostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Theranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Theranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Theranostics Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Theranostics Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Theranostics Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Theranostics Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Theranostics Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Theranostics Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Theranostics Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Theranostics Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Theranostics Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cardiology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cardiology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cardiology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Genomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Genomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Genomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Proteomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Proteomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Proteomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Metabolomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Metabolomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Metabolomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Biomarkers Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Biomarkers Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Biomarkers Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • JAPAN
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • CHINA
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: China 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: China 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • EUROPE
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Theranostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Theranostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • FRANCE
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: France 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: France 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: France 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: France 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • GERMANY
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Germany 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Germany 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Italy 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Italy 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: UK 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: UK 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: UK 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: UK 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Spain 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Spain 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Russia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Russia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Theranostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Australia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Australia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • INDIA
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 221: India Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: India 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: India 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: India 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: India 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: South Korea 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: South Korea 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Theranostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Latin America 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Latin America 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Argentina 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Argentina 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Brazil 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Brazil 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Mexico 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Mexico 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Mexico 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Theranostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 322: Middle East 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 334: Middle East 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 337: Iran 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 343: Iran 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 346: Iran 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 349: Israel 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 355: Israel 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 358: Israel 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 373: UAE 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 379: UAE 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 382: UAE 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
  • AFRICA
    • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 397: Africa 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 403: Africa 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 406: Africa 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제